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Epithelial ovarian cancer (EOC) is the fourth most common 
cause of death from cancer in women in the Western world. 
More than 70% of patients are diagnosed with advanced dis-
ease, where 5-year survival rates are less than 30%. Because 
EOC typically cause few specific symptoms, early detection of 
EOC has been a challenge to improve clinical outcome. 
The triage of women at high risk for EOC before surgery is of 
critical importance for patient having a pelvic mass. The surgi-
cal approach for benign and malignant ovarian tumors differs 
fundamentally, and preoperative diagnosis allows for careful 
planning of surgical procedure and referral to high volume 
centers. In fact, patients with EOC managed by gynecologic 
oncologists and at high-volume institutions are more likely to 
undergo complete surgical staging and optimal cytoreductive 
surgery with fewer complications and better survival than pa-
tients managed by less-experienced surgeons [1,2]. Therefore, 
much effort have been devoted until today for the identifica-
tion of a simple and effective test that can screen EOC at an 
early stage and make reliable diagnosis preoperatively. 
The serum tumor marker CA-125 was discovered in 1981, 
and became a milestone in the pathway for the develop-
ment of a non-invasive and biochemical approach to the 
diagnosis of EOC. Multimodal screening using annual CA-125 
and second-line transvaginal ultrasound scan had showed 
encouraging results, that is, sensitivity (SN) 89.5%, specificity 
(SP) 99.8%, and positive-predictive value 35.1% among post-
menopausal women in the UK Collaborative Trial of Ovarian 
Cancer Screening (UKCTOCS) study [3]. However, similar ran-
domized controlled trials performed in the USA, The Prostate, 
Lung, Colorectal and Ovarian (PLCO) Cancer Screening study, 
recently reported that simultaneous screening CA-125 and 
transvaginal ultrasound compared with usual care did not 
reduce ovarian cancer mortality in post-menopausal women, 
and consequent diagnostic evaluation from false positive 
screening was associated with complications [4]. Although 
the effect of screening on mortality of the UKCTOCS is pend-
ing, the mortality results of PLCO imply that recent screening 
tools are still unsatisfactory. In fact, measurement of CA-125 
has several clinical limitations, because elevation of CA-125 
is only observed in less than half of patients with early-stage 
EOC and in about 80% of all EOC patients. In addition, serum 
CA-125 concentrations may be affected by common benign 
gynecologic disorders such as leiomyoma, endometriosis 
and pelvic inflammatory disease, which are more prevalent in 
premenopausal women. Therefore, there has been an urgent 
need for the development of a novel biomarker with higher 
accuracy. 
The human epididymal secretory protein E4 (HE4) was first 
identified at 1990 on differential cDNA screening of human 
epididymal tissue. HE4 is one of the most up-regulated genes 
in EOC based on gene expression profiles, and has been re-
ported to have superiority over CA-125 as a biomarker for 
EOC. Among various biomarkers including CA-125, CA 72-4, 
and osteopontin, HE4 had the highest sensitivity for detect-
ing ovarian cancer (SN, 72.9%; SP, 95%), especially for stage I 
disease [5]. Moreover, recent studies have reported that HE4 
is complimentary to CA-125 as it is not falsely increased in 
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benign gynecologic disorders contrary to CA-125 . The combi-
nation of CA-125 with HE4 achieved the highest sensitivity for 
the detection of EOC compared with other biomarkers [5,6], 
and better diagnostic performance (SN, 92.9%; SP, 95%) be-
tween EOC, endometrial cancer, endometriosis, and healthy 
controls compared with HE4 (SN 78.6%) or CA-125  (SN 78.6%) 
alone [7]. For these reasons, the risk of ovarian malignancy 
algorithm (ROMA) was constructed as a predictive index to 
estimate the risk of EOC in women presenting with a pelvic 
mass based on the two pilot studies [5,6]. ROMA takes into 
account the serum concentration of CA-125 and HE4, and the 
menopausal status. A recent study demonstrated the superi-
ority of ROMA compared with risk of malignancy index (RMI), 
an algorithm employing ultrasound findings and architectural 
features of pelvic masses, CA-125 levels and menopausal sta-
tus (SN 94.3% vs. 84.6% at a set SP of 75%) [8]. Of particular in-
terest, the ROMA showed a higher sensitivity for patients with 
stage I and II EOC, and for those with tumors grossly confined 
to the pelvis, or with less than 2 cm disease in the upper ab-
domen [9]. Nowadays, searching for the optimal multi-marker 
assay is still ongoing for the early detection of ovarian cancer 
[10]. 
In this issue of Journal of Gynecologic Oncology, Partheen 
et al. [11] evaluated the diagnostic performance of HE4 for 
the detection of ovarian cancer, compared with CA-125 alone 
and in combination of the two. HE4 achieved better sensitiv-
ity than CA-125 in premenopausal group (80.9% vs. 76.2% at 
a set SP of 75%), which confirmed the clinical value of HE4, 
especially in premenopausal women. However, the specificity 
of HE4 was significantly lower than that of CA-125 in post-
menopausal patients (SN 80.6%, SP 75% vs. SN 82.8%, SP 83%), 
and the sensitivity of HE4 was not superior to that of CA-125 
in early stage tumors (SN 59.6%, SP 75% vs. SN 61.7%, SP 80%), 
which is contradictory to other investigations. Is CA-125 still 
the best biomarker for the diagnosis of EOC? There are several 
limitations in the study. Owing to the study design, there may 
be a possibility of quality problems in the preserved serum. 
The sample distribution was limited and different from those 
of other investigations. The cut-off of HE4 is not determined 
and varies among comparable reports. Indeed, the history of 
HE4 is relatively short and HE4 is subject to clinical validation. 
Therefore, both HE4 and CA-125 should be included in more 
prospective studies in the future. 
In another paper in this issue, Kang et al. [12] dealt with the 
utilization of CA-125 as a predictive marker for recurrence. 
They collected data from two high-volume institutions and 
scrutinized the correlation between post-treatment nadir CA-
125 and progression free survival in patients with advanced 
ovarian cancer who had achieved complete remission. An 
acknowledgeable finding of this paper is the determination of 
a reasonable cut-off value of CA-125 that can be used for the 
identification of high-risk patients. Although there were some 
limitations including sample size and population, the validat-
ed cut-off value of CA-125 may be used reliably to stratify the 
post-treatment patients or to plan a novel consolidation treat-
ment for the better outcome of the poor prognostic group. 
In the future, we expect other biomarkers including HE4 
could be used for monitoring the response to therapy and 
the course of the disease as CA-125. Further studies should 
be performed to provide evidence not only on the diagnostic 
value of tumor biomarkers but also their potential prognostic 
or predictive value for the management of EOC patients. 
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